中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

FibroTouch与B超、CT对脂肪肝的诊断价值比较

李静波 刘姝 温博 高楠 王炳元

引用本文:
Citation:

FibroTouch与B超、CT对脂肪肝的诊断价值比较

DOI: 10.3969/j.issn.1001-5256.2016.03.011
详细信息
  • 中图分类号: R575.5

Clinical significance of Fibro Touch,ultrasound,and computed tomography in diagnosis of fatty liver disease: a comparative analysis

  • 摘要:

    目的探讨影像引导瞬时弹性成像系统Fibro Touch脂肪衰减参数(FAP)对脂肪肝诊断的意义。方法以2014年1月-12月在中国医科大学附属第一医院体检的1080例体检者为研究对象,统计所有人员的肝脏FAP、肝脏彩超结果和肝脏CT平扫肝/脾CT比值。计量资料组间比较采用Kruskal-Wallis H检验,采用Kappa一致性系数和ROC曲线比较FAP与肝脏彩超结果和肝脏CT平扫肝/脾CT比值诊断脂肪肝的一致性及其诊断价值。结果通过肝脏B超诊断脂肪肝阴性336例(31.11%),阳性744例(68.89%);参照B超结果,Fibro Touch的敏感性及特异性分别为80.5%和75.3%。通过肝脏CT诊断脂肪肝阴性(0级)821例(76.02%)、阳性259例,其中轻度(1级)216例、中度(2级)34例、重度(3级)9例;参照CT结果,Fibro Touch的敏感性及特异性分别为95.4%和47.0%,B超的敏感性及特异性分别为93.1%和36.8%。Fibro Touch诊断脂肪肝结果与B超有较高的一致性(kappa系数=0.597,P<0.0001);与CT的一致性较低(...

     

  • [1]FAN JG.Epidemiology of alcoholic and nonalcoholic fatty liver disease in China[J].J Gastroenterol Hepatol,2013,28(Suppl 1):11-17.
    [2]FESTI D,SCHIUMERINI R,MARZI L,et al.Review article:the diagnosis of non-alcoholic fatty liver disease-availability and accuracy of non-invasive methods[J].Aliment Pharmacol Ther,2013,37(4):392-400.
    [3]ANSTEE QM,TARGHER G,DAY CP.Progression of NAFLD to diabetes mellitus,cardiovascular disease or cirrhosis[J].Nat Rev Gastroenterol Hepatol,2013,10(6):330-344.
    [4]European Association for the study of the Liver.EASL clinical practical guidelines:management of alcoholic liver disease[J].J Hepatol,2012,57(2):399-420.
    [5]Expert Committee on the Diagnosis and Management of Fatty Liver Disease,Chinese Medical Association.Recommendation for the standardization of diagnosis and treatment of fatty liver disease[J].J Clin Hepatol,2013,29(9):652-655.(in Chinese)中国医师协会脂肪性肝病专家委员会.脂肪性肝病诊疗规范化的专家建议[J].临床肝胆病杂志,2013,29(9):652-655.
    [6]NASCIMBENI F,PAIS R,BELLENTANI S,et al.From NAFLD in clinical practice to answers from guidelines[J].J Hepatol,2013,59(4):859-871.
    [7]CASTERRA L,VILGRAIN V,ANGULO P.Noinvasive evaluation of NAFLD[J].Nat Rev Gastroenterol Hepatol,2013,10(11):666-675.
    [8]KHOV N,SHARMA A,RILEY TR.Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease[J].World J Gastroenterol,2014,20(22):6821-6825.
    [9]MYERS RP,POLLETT A,KIRSCH R,et al.Controlled attenuation parameter(CAP):a noninvasive method for the detection of hepatic steatosis based on transient elastography[J].Liver Int,2012,32(6):902-910.
    [10]CHAN WK,NIK MUSTAPHA NR,MAHADEVA S.Controlled attenuation parameter for the detection and quantification of hepatic steatosis in non-alcoholic fatty liver disease[J].J Gastroenterol Hepatol,2014,29(7):1470-1476.
    [11]CHON YE,JUNG KS,KIM SU,et al.Controlled attenuation parameter(CAP)for detection of hepatic steatosis in patients with chronic liver diseases:a prospective study of a native Korean population[J].Liver Int,2014,34(1):102-109.
    [12] SASSO M,TENGHER-BARNA I,ZIOL M,et al.Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan:validation in chronic hepatitis C[J].J Viral Hepat,2012,19(4):244-253.
    [13]SCAGLIONI F,CICCIA S,MARION M,et al.ASH and NASH[J].Dig Dis,2011,29(2):202-210.
    [14] VERNON G,BARANOVA A,YOUNOSIS ZM.Systematic review:the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults[J].Aliment Pharmacol Ther,2011,34(3):274-285.
    [15]WANG FS,FAN JG,ZHANG Z,et al.The global burden of liver disease:the major impact of China[J].Hepatology,2014,60(6):2099-2108.
    [16]HU X,HUANG Y,BAO Z,et al.Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units[J].BMC Gastroenterol,2012,12(35):123.
    [17]CARVALHANA S,LEITO J,ALVES AC,et al.How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population:correlation with ultrasound[J].Liver Int,2014,34(6):e111-e117.
    [18]FERRAIOLI G,TINELLI C,LISSANDRIN R,et al.Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis[J].World J Gastroenterol,2014,20(21):6626-6631.
    [19]KUMAR M,RASTOGI A,SINGH T,et al.Controlled attenuation parameter for non-invasive assessment of hepatic steatosis:does etiology affect performance?[J].J Gastroenterol Hepatol,2013,28(7):1194-1201.
    [20]SCHWEZER NF,SPRINGER F,SCHRAML C,et al.Noninvasive assessment and quantification of liver steatosis by ultrasound,computed tomography and magnetic resonance[J].J Hepatol,2009,51(3):433-445.
    [21]MEHTA SR,THOMAS EL,BELL JD,et al.Noninvasive means of measuring hepatic fat content[J].World J Gastroenterol,2008,13(22):3476-3483.
    [22]ZEB I,LI D,NASIR KG,et al.Computed tomography scans in the evaluation of fatty liver disease in a population based study:the multi-ethnic study of atherosclerosis[J].Acad Radiol,2012,19(7):811-818.
    [23] MYERS RP,POLLETT A,KIRSCH R,et al.Controlled attenuation parameter(CAP):a noninvasive method for the detection of hepatic steatosis based on transient elastography[J].Liver Int,2012,32(6):902-910.
    [24]SHEN Y,ZHANG J,CAI H,et al.Identifying patients with chronic hepatitis B at high risk of type 2 diabetes mellitus:a cross-sectional study with pair-matched controls[J].BMC Gastroenterology,2015,15(1):32.
    [25]PARK SK,SEO MH,SHIN HC,et al.Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men:5-year prospective cohort study[J].Hepatology,2013,57(4):1378-1383.
    [26]de LEDINGHEN V,VERGNIOL J,FOUCHER J,et al.Non-invasive diagnosis of liver steatosis using controlled attenuation parameter(CAP)and transient elastography[J].Liver Int,2012,32(6):911-918.
  • 加载中
计量
  • 文章访问数:  2577
  • HTML全文浏览量:  82
  • PDF下载量:  451
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-08-08
  • 出版日期:  2016-03-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回